Neuland Laboratories Ltd
NSE:NEULANDLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Berkeley Energia Ltd
ASX:BKY
|
UK |
|
A
|
Amata VN PCL
SET:AMATAV
|
TH |
|
Voltronic Power Technology Corp
TWSE:6409
|
TW |
|
Focus Financial Partners Inc
F:2JE
|
US |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
188.9B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Neuland Laboratories Ltd
Glance View
Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Neuland Laboratories Ltd is 14.9%, which is below its 3-year median of 20.6%.
Over the last 3 years, Neuland Laboratories Ltd’s Operating Margin has increased from 13.6% to 14.9%. During this period, it reached a low of 12.4% on Jun 30, 2025 and a high of 27.4% on Mar 31, 2024.